Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See analysts' views on LOPE stock.
Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Stifel analyst Dara Azar initiated coverage on Enliven Therapeutics Inc (NASDAQ:ELVN) with a Buy rating and announced a price target of $60.
Enliven Therapeutics shares closed at $33.63 on Monday.
See how other analysts view this stock.
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on…
Wall Street analysts changed outlook on top names. See full ratings page for upgrades, downgrades, and initiations. Analysts view…
Top Wall Street analysts change outlook on top names. See analyst ratings page for changes, including…
Top Wall Street analysts changed their outlook on top names. See upgrades, downgrades & initiations on analyst ratings page.…
Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. Check…
Top Wall Street analysts upgraded LEA, BAH, TRV, and CGNX stocks, with higher price targets. See what analysts think of other…
